Ovarian Cancer Coverage from Every Angle

Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

By: Melissa Steele-Ogus
Posted: Wednesday, November 18, 2020

A study conducted by Kimihiko Ito, MD, of the Kansai Rosai Hospital Japan, found that the combination therapy of oral cyclophosphamide and bevacizumab may prove to be an effective therapy for recurrent ovarian or peritoneal cancer. The results were published in a poster session of the 2020 International Gynecologic Cancer Society (IGCS) Annual Global Meeting (Abstract 1331).

A total of 22 patients were enrolled in the study between August 2014 and June 2020. Of the total patient population, 20 patients had ovarian cancer, and 2 had peritoneal cancer. The median patient age was 60 years (range, 37–81 years), and the median follow-up time was 18.9 months (range, 5.0–51.5 months). Patients received 50 mg/day of cyclophosphamide orally and bevacizumab at 15 mg/kg intravenously every 3 weeks as one cycle. Patients had received a median of 2.5 previous chemotherapy regimens.

Complete response was achieved in two patients, and a partial response was achieved in one. Stable disease was seen in five patients, and the response rate was 13.6%. Median progression-free survival was 5.3 months, with a range between 0.8 and 23.5 months. Median overall survival from treatment initiation was 9.2 months (range, 4.8–51.5+ months). Treatment was discontinued in 18 patients due to adverse effects (n = 3) and disease progression (n = 15). Grade 2 toxicities consisted of neutropenia, protein urea, hypertension, and esophagitis.

The researchers concluded that the combination therapy might be “used safely in patients who have become difficult to treat after second-line chemotherapy.”

Disclosure: No disclosure information was provided for the study authors.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.